Cost Savings

Healthcare expenses are out of control, and high costs are putting pressure on employers and members alike. Too often, innovation in healthcare drives minor improvements at an increased cost.

Procedures using Regenexx injectates are a disruptive innovation that treat common orthopedic injuries. The Regenexx innovation can reduce the cost of individual orthopedic surgeries by up to 70%. We leverage more than 15 years of registry data and published research to deliver value to employers and members.

Member Experience

The Regenexx Corporate Program prioritizes providing a seamless and supportive experience for your members. We understand that the journey toward recovery can be challenging, and we are here to make it as smooth as possible.

Key Features of the Member Experience

Education Center Support: From the initial consultation to post-treatment follow-up, our team is committed to providing comprehensive support.

New Regenexx provider patient evaluation: During an appointment, the physician will perform an exhaustive evaluation to identify the root cause of their pain by utilizing a full range of motion test, SANS evaluation, and advanced ultrasound imaging when needed. Results are explained in detail and the patient will be assessed for candidacy based on the extensive Regenexx Provider Patient Registry.

Innovative treatments: Access to state-of-the-art regenerative medicine techniques that promote faster recovery and better outcomes.

Utilization Model

If any healthcare solution is to achieve its potential, it must be actively utilized by members, which requires clear and effective communication strategies to promote awareness. We target full utilization and report back to employers on the effectiveness of member engagement strategies.

Regenexx employs a multifaceted communication strategy to ensure members are well-informed about the benefits and availability of procedures using Regenexx injectates. We find this approach maximizes program awareness and participation. This leads to improved utilization of the high-quality, high-value Regenexx approach, which can intervene on up to 70% of unnecessary orthopedic surgeries.

Benefits Cards

We send co-branded Benefits Cards to members. The benefits card mailers detail the various conditions physicians in the licensed Regenexx network treat, such as back pain, knee pain, and more, providing members with essential information about how the Regenexx approach can help them.

Targeted Outreach

Utilizing claims data; we can help identify members who are likely to undergo orthopedic surgery. We reach out to these members to ensure they are aware of their Regenexx benefit and that procedures using Regenexx injectates are a less invasive alternative to traditional surgery.

Educational Webinars

Ongoing live webinars provide an easy and accessible way for members to get their questions answered and learn more about Regenexx benefits and procedures using Regenexx injectates.

We build a site for each group outlining members’ specific benefits. Our national Regenexx Education Center team is available to answer any questions members may have Monday through Friday by phone. There is no cost for our utilization model.

Utilization Review

Utilization review is offered as a standard part of the Regenexx Corporate Program. Regenexx reviews and approves every treatment using Regenexx injectates to make sure physicians in the licensed Regenexx network deliver high-value services to members. We start with two fundamental questions:

  1. Is the procedure using Regenexx injectates appropriate for the patient?
  2. Is there a cost-savings opportunity compared to the surgical alternative?

The utilization review process also ensures that conservative care is the first step. Physicians may recommend that patients receive physical therapy or a low-dose steroid injection prior to being considered a candidate for a procedure using Regenexx injectates unless their condition has already failed to respond to conservative care.

Our utilization review process combines our expertise and clinical integrity. Regenexx understands that to accurately calculate savings, it is essential to consider how often procedures to treat orthopedic issues fail and lead to surgery. We only move forward with procedures for patients with good candidacy ratings to support cost savings.

 

Brokers

We partner with brokers to deliver a musculoskeletal solution to your self-funded groups that is 70% less expensive than traditional surgery. In addition, our team is focused on supporting you with clients and prospects.

TPAs

The Regenexx Corporate Program partners with over 100 TPAs (third-party administrators) to process claims for self-funded clients. After a plan is amended, TPAs may process member claims in different ways based on their preferences. Contact us to learn more and to find out if we have worked with your or your client’s TPA before.

Stop Loss Carrier List

The Regenexx Corporate Program works with nearly 100 stop-loss carriers. Most carriers will agree to “mirror” the summary plan description (SPD) amendment. Our sales team can support you on a call with the stop-loss carrier. We typically provide a cost-savings study along with our safety paper, which demonstrates that the risks of procedures with Regenexx injectates are similar to other injection-based treatments and that the costs are significantly lower than traditional orthopedic surgery.

Regenexx Impact Study

As an insurance broker, your clients rely on you to provide them with the best options for managing healthcare costs while maintaining high standards of care. Request an Impact Study to receive an overview of the savings opportunity for clients and summary materials for client meetings. This helps clients make a fully informed decision about adding Regenexx as a benefit. We use de-identified claims data in these studies.

Implementing Regenexx was very easy. My team would definitely recommend any healthcare plan get in touch with Regenexx to find out about the benefits they can bring to your employees.

Linda Wyatt
VP of Human Resources, Edward C. Levy